





-
Treatment Pathway and Clinical Outcomesof the Population with Muscle‑invasiveBladder Cancer in Italy: A Real‑world Analysiswith Administrative Databases
Paolo Luraghi, Valentina Perrone, Daniela Castelletti, Serena Losi, Matteo Risi, Stefania Mazzoni, Luca Degli Esposti, Lorenzo AntonuzzoPublisher: Advances in therapy
Publication date: 29 novembre 2025ABSTRACTIntroduction: In Italy, real-world data on muscle-invasive bladder cancer (MIBC) are scanty. This analysis exploited administrative databases to describe the clinical characteristics and treatment outcomes of patients with MIBC. Methods: Adults hospitalized for non-metastatic bladder cancer who underwent cystectomy in 2018 were proxied for MIBC. The following variables were examined: demographic and clinical characteristics, number… Read More »Treatment Pathway and Clinical Outcomesof the Population with Muscle‑invasiveBladder Cancer in Italy: A Real‑world Analysiswith Administrative Databases
-
Epidemiologic Characteristics Determining the Choice ofDirect-Acting Antiviral Therapy in HCV Patients: An ItalianReal-World Evidence Study
Nicola Pugliese, Fabio Conti, Valerio Rosato, Paolo Gallo, Stefano Gitto, Marco Riglietta, Francesca Frigerio, Valentina Perrone, Chiara Veronesi, Maria Cappuccilli, Luca Degli Esposti, Alessandra Mangia, Loreta A. Kondili; other co-authors PathogensPublication date: 18 novembre 2025AbstractPangenotypic direct-acting antivirals (pDAAs) have transformed hepatitis C virus (HCV) treatment. In Italy, sofosbuvir/velpatasvir (SOF/VEL) and glecaprevir/pibrentasvir (GLE/PIB) are available. While both show similar efficacy, differences in patient profilesand potential drug–drug interactions (DDIs) may influence treatment choice. This study examined factors affecting pDAA selection and potential prescribing gaps. Using administrative databases (2018–2023) covering 3.7 million… Read More »Epidemiologic Characteristics Determining the Choice ofDirect-Acting Antiviral Therapy in HCV Patients: An ItalianReal-World Evidence Study
-
Ranolazine in patients with chronic coronarysyndromes: real-world data provide newevidence on the antiarrhythmic properties of the drug
Stefano Fumagalli, Melania Dovizio, Stefania Mazzoni, Luca Degli Esposti, Emanuele Santamaria, Giulia Spanalatte, Carlo Fumagalli, Camilla Cagnoni, Arianna Tariello, Elisabetta Cerbai, Niccolò MarchionniPublisher: European Heart Journal Cardiovascular Pharmacotherapy
Publication date: 05 Novembre 2025Aims: Ranolazine (Ran) is an anti-anginal drug inhibiting late sodium current, an action possibly hindering arrhythmias onset. Indeed, some evidence supports the anti-arrhythmic effects of Ran. The aim of this study, which evaluated Italian patients withchronic coronary syndrome (CCS), was to investigate whether Ran, as an add-on therapy, was associated with a lower incidenceof atrial… Read More »Ranolazine in patients with chronic coronarysyndromes: real-world data provide newevidence on the antiarrhythmic properties of the drug
-
Characteristics, therapeutic pathway and the economicburden of patients with drug-resistantepilepsy: A real-worldanalysis following the introduction of cenobamate inItaly
Valentina Perrone, Chiara Veronesi, Maria Cappuccilli, Margherita Andretta, Marcello Bacca, Antonietta Barbieri, Fausto Bartolini, Alessandro Brega, Mariarosaria Cillo, Francesco Colasuonno, Stefania Dell’Orco, Fulvio Ferrante, Stefano Grego, Antonella Lavalle, Daniela Mancini, Maurizio Pastorello, Romina Pagliaro, Cataldo Procacci, Camilla Scandolara, Patrizia Schiavone, Loredana Ubertazzo, Paola Valponti, Adriano Vercellone, Alberto Zucchi, Maria Ciappetta, Domenico Lucatelli, Andrea Cinti Luciani, Luca Degli EspostiPublisher: Epilepsia
Publication date: 24 ottobre 2025Abstract Objectives: Drug-resistant epilepsy (DRE) remains a major clinical challenge, affecting approximately one-thirdof patients with epilepsy. Cenobamate, a novel antiseizure medication (ASM) approved in Italy in 2022, has shown promisein clinical trials. However, real-world data on its use, especially economic evaluations, remain limited. This analysis assessed the impact of cenobamate in Italian clinical practice, focusing… Read More »Characteristics, therapeutic pathway and the economicburden of patients with drug-resistantepilepsy: A real-worldanalysis following the introduction of cenobamate inItaly
-
The economic impact of multimorbidity in Italy:evaluation of direct costs and scenario analysis ofpatients with type 2 diabetes, heart failure, andchronic kidney disease using real-world data
Valentina Perrone, Claudio Ripellino, Maria Cappuccilli, Melania Leogrande, Andrea Cinti Luciani, Luca Degli EspostiPublisher: Global & Regional Health Technology Assessment
Publication date: 22 settembre 2025ABSTRACTObjectives: This study aimed to evaluate the healthcare costs associated with managing type 2 diabetes (T2D),chronic kidney disease (CKD), and heart failure (HF) in Italy. Specifically, the research investigated the economicimpact on the Italian National Health System due to the increased clinical complexity and multimorbidity amongpatients with these conditions.Methods: A predictive model was developed to… Read More »The economic impact of multimorbidity in Italy:evaluation of direct costs and scenario analysis ofpatients with type 2 diabetes, heart failure, andchronic kidney disease using real-world data